Antiaging Quantum Living Inc.

What they do

The company operates online advertising through www.dazhong368.com, serving the Greater New York area with listings for real estate, accounting, legal, and other professional services, generating revenue from advertising fees. In fiscal 2026, management initiated a strategic shift away from third-party platform services to focus on the supply and distribution of proprietary brand health products and therapy services, with subsidiaries in BVI, Hong Kong, and China.

Revenue drivers

• Online advertising (dazhong368.com) — Generates revenue from fees charged for advertisements posted on the website, historically the company's primary revenue source; annual revenue reached $817,898 in 2025.
• Health products and therapy services (new) — New business direction, intended to supply proprietary brand health products and therapy services; no segment revenue breakdown provided in filings.

Recent performance

For fiscal year ended March 31, 2026, revenue was $1.03 million, up 26.5% from $817,898 in 2025, but net loss widened to $837,646 from $720,409. Gross margin improved to 67.9% from 52.4%, yet SG&A expenses rose 26.2% to $1.54 million, contributing to an operating loss of $835,401. Quarterly revenue dropped sharply to $12,491 in the three months ended March 31, 2026, from $340,292 in the prior quarter. As of March 31, 2026, cash was $503,486, total assets $1.7 million, total liabilities $2.4 million, and shareholder equity was negative at -$675,871.

Strategy

Management pivoted to focus exclusively on supply and distribution of proprietary health products and therapy services, ceasing online platform technical operations in phases through September 2025 and January 2026. The company established entities in BVI, Hong Kong, and China (Dao Ling Doctor Hangzhou, Zhejiang, and Huzhou) to support expansion into Asia-Pacific and Chinese markets. The transition is intended to enhance brand value and control over the product supply chain, despite near-term financial impact.

Risks

• Going concern / negative equity — Shareholder equity is negative (-$675,871) and the company has sustained losses for five consecutive years, casting doubt on its ability to continue as a going concern.
• Revenue collapse — Quarterly revenue fell from $390,164 (September 2025) to $12,491 (March 2026), indicating a near-total loss of the legacy advertising business.
• Strategic transition execution — The shift to health products is untested and involves operations in China, subject to regulatory, cultural, and execution risks; no revenue from new segments has been reported yet.
• Control and management changes — Three changes in control and multiple CEO/CFO and auditor changes since 2019 create governance and operational instability.

Outlook

Management expects the transition to health products to improve long-term brand value and supply chain control, but acknowledges material near-term impact and comparability issues. No specific future revenue or profitability guidance was provided in the filings.